BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

PhenoMed Initiating Clinical Trials Program For SARS And Other Infectious Diseases


10/19/2005 5:09:47 PM

KUALA LUMPUR, Malaysia, Jan. 26 /PRNewswire/ -- PhenoMed Sdn Bhd, a development-stage disease management and medical-pharmaceutical therapeutic company, announces the initiation of its clinical trials program for infectious diseases.

"PhenoMed is announcing that it will begin collecting information from government agencies, physicians and individual patients interested in participating in the company's clinical trials program. We are working closely with our US partner, GenoMed, Inc., and that company's CEO and Chief Medical Officer, Dr. David Moskowitz, in helping to sign up interested parties," said Ezehan Reza Kamaluddin, PhenoMed's interim Chief Operating Officer. "There is a worldwide need for disease management and targeted pharmaceutical therapeutics directed at infectious disease. Malaysia's disease management needs are ever-present and PhenoMed wants to do all it can to help in meeting the country's healthcare needs. The immediate concerns over avian flu in the region highlights this need."

PhenoMed's US partner, GenoMed, believes it has discovered a way to accomplish the equivalent of vaccination against all viruses, a kind of "universal vaccine" against most viral diseases. The method involves blocking angiotensin II, an approach already known to be extremely safe from its use, for other purposes, in hundreds of millions of patients since 1978. This patent-pending method is presently under study by the National Institute of Allergy and Infectious Diseases (NIAID), part of NIH, to test the Company's compounds in tissue culture assays to evaluate potential activity against influenza (the flu) and SARS.

About PhenoMed, Sdn Bhd

PhenoMed is a development-stage disease management and medical- pharmaceutical therapeutic company, with its primary goal being the improvement of patient outcomes through the discovery and application of "genome-aware therapeutics(TM)". PhenoMed is building a network of physician and health services organizations to quickly expand its medical and therapeutic service offerings throughout the Asia-Pacific region. Founded in 2003, PhenoMed is a privately held company located in Kuala Lumpur, Malaysia. For more information about the company, please visit http://www.phenomed.net/.

PhenoMed Contact: Corporate Headquarters Ezehan Reza Kamaluddin Chief Operating Officer (Interim) 28-1, Level 1, Jalan 28/70A Desa Sri Hartamas 50480 Kuala Lumpur, Malaysia ezehan@dnaphenomics.comhttp://www.phenomed.net/ About GenoMed, Inc.

GenoMed, Inc. is a next generation disease management company whose mission is the improvement of patient outcomes through the identification of molecular pathways that cause disease. As first reported in a St. Louis Business Journal article (http://www.stlouis.bizjournals.com/stlouis/stories/2002/05/13/story8.html), the company has applied for patents based on its finding that the ACE gene is associated with a large number of common diseases including virtually all autoimmune diseases. GenoMed is currently conducting worldwide clinical trials for SARS and influenza A (the flu). In September of 2003, GenoMed obtained an 88% cure rate for this treatment approach against another lethal viral disease, West Nile virus encephalitis. These results will be published soon.

GenoMed Contact: David W. Moskowitz MD, MA (Oxon.), FACP 314-977-0110 fax: 314-977-0042 dwmoskowitz@genomedics.comhttp://www.genomedics.com/

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com/.

PhenoMed Sdn Bhd

CONTACT: Ezehan Reza Kamaluddin, Chief Operating Officer (Interim),PhenoMed, ezehan@dnaphenomics.com; or David W. Moskowitz MD, MA (Oxon.), FACP,GenoMed, +1-314-977-0110, fax: +1-314-977-0042, dwmoskowitz@genomedics.com



Read at BioSpace.com

PhenoMed
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES